Sophie Paczesny | Immunotherapy | Best Researcher Award

Published on by Cell Biologist

Prof. Sophie Paczesny | Immunotherapy | Best Researcher Award

Prof. Sophie Paczesny, Medical Univeristy of South Carolina, United States

Dr. Sophie Paczesny, M.D., Ph.D., is an internationally recognized leader in immunology and cancer research. Currently, she serves as Professor of Immunology & Pediatrics and the Sally Abney Rose Endowed Chair in Cancer Stem Cell Biology at the Medical University of South Carolina (MUSC). She is also Co-Leader of the Cancer Biology & Immunology Program at the Hollings Cancer Center. With a deep commitment to improving outcomes in hematopoietic cell transplantation, her translational research bridges clinical and laboratory advances in graft-versus-host disease (GVHD), biomarkers, and tumor immunology. Her work has shaped diagnostic and therapeutic strategies across pediatric and adult oncology. Dr. Paczesny’s pioneering studies on dendritic cell vaccines and immune reconstitution have led to impactful, high-citation publications in journals like Blood, JCI Insight, and Journal of Clinical Oncology. She continues to mentor the next generation of physician-scientists while advancing cutting-edge immune-oncology research globally.

Publication Profile: 

Orcid

Scopus

✅ Strengths for the Award:

  1. Pioneering Work in Immunology & Transplantation
    Dr. Paczesny has significantly advanced our understanding of graft-versus-host disease (GVHD) through the development of novel biomarkers, improving diagnostics, patient stratification, and therapeutic decisions in hematopoietic cell transplantation.

  2. High-Impact Publications
    With over 20 influential publications, including in Blood, JCI Insight, Journal of Clinical Oncology, and British Journal of Haematology, she has made consistent contributions to high-impact journals, underscoring the translational value of her work.

  3. Strong Interdisciplinary Background
    Her dual degrees (M.D., Ph.D.), combined with training across mathematics, life sciences, tumor immunology, and cell therapy, enable her to bridge basic science and clinical application effectively.

  4. Leadership and Mentorship
    Holding senior positions such as Professor, Endowed Chair, and Program Co-Leader at MUSC, she demonstrates strong leadership and commitment to fostering academic growth in immunology and pediatrics.

  5. Global and Collaborative Impact
    Her participation in international collaborations and consortia (e.g., Pediatric Transplant and Cellular Therapy Consortium) highlights her global influence and scientific diplomacy.

  6. Innovative Clinical Translation
    She led or contributed to the development of decision-support tools (e.g., biomarker-based decision trees for VOD/SOS), which have the potential to shift real-world clinical practices.

⚙️ Areas for Improvement:

  1. Outreach & Visibility
    Despite her extensive contributions, Dr. Paczesny may benefit from more frequent keynote talks, scientific media presence, or public engagement efforts to raise broader awareness of her work among policymakers, patients, and industry.

  2. Startup/Commercial Translation
    While highly research-driven, expanding into biotech or diagnostic tool commercialization could further translate her biomarker discoveries into scalable clinical solutions.

  3. Grant Leadership Details
    The provided information doesn’t detail the scope of grants led (e.g., NIH R01s, consortia P01s). Adding these details could strengthen evaluations by funding and award committees.

🎓 Education:

Dr. Paczesny began her academic journey in France, earning a B.S. in Mathematics and Life Sciences from the Academy of Nancy-Metz (1985–1989). She pursued her M.D. at the University of Strasbourg, completing her medical degree in 1995. Her passion for cellular therapies led her to obtain an M.S. in Cell Therapy and Biology of Hematopoietic Cells from the University of Paris VII in 1999. She continued her scientific training by earning a Ph.D. in Tumor Immunology at the same institution in 2004. Her educational background reflects a unique blend of clinical training and basic science, providing the foundation for her translational research in immunology and cancer biology. This multidisciplinary training has enabled her to tackle complex clinical problems like graft-versus-host disease and immune response modulation from both therapeutic and mechanistic angles.

🩺 Professional Experience:

Dr. Sophie Paczesny has held academic and clinical positions in both Europe and the United States. She began her faculty career as Assistant Professor of Pediatrics at the University and Hospitals of Nancy (2003–2005). She transitioned to the U.S. as Assistant Professor of Pediatrics and Communicable Diseases at the University of Michigan (2009–2012). From 2012–2015, she served as Associate Professor at Indiana University School of Medicine, holding appointments in Pediatrics, Microbiology, and Immunology. She also contributed to the Melvin and Bren Simon Cancer Center. Currently, she is a Professor at the Medical University of South Carolina (MUSC), where she leads research and training efforts in immunology and cancer biology. Across all roles, she has led NIH-funded programs, advanced biomarker research, mentored junior investigators, and contributed to the development of immunotherapeutic approaches in hematopoietic cell transplantation and cancer.

🏅 Honors and Awards:

Dr. Paczesny has received numerous honors recognizing her contributions to science and medicine. In 1999, she earned Second Prize at the Avicenne Hospital Research Meeting in Paris. In 2000, she was awarded the Médaille d’Argent (Silver Medal) from Paris University Hospitals’ residency program. That same year, she co-received First Prize for Best Fellow Academic Work in France, acknowledging her early excellence in clinical and research training. Her ongoing research has been consistently supported by competitive grants and featured in high-impact journals, highlighting her leadership in biomarker discovery and immune-oncology. As an endowed chair at MUSC and an invited speaker at leading international conferences, her work continues to gain recognition. These awards underscore both her clinical insight and scientific innovation, particularly in the fields of transplant immunology and cancer immunotherapy.

🔬 Research Focus:

Dr. Paczesny’s research is centered on translational immunology, with a special focus on graft-versus-host disease (GVHD), immune reconstitution, and cancer immunotherapy. She has pioneered the use of biomarkers to predict outcomes and complications in hematopoietic stem cell transplantation, including veno-occlusive disease and chronic GVHD. Her studies have uncovered novel immune pathways and prognostic indicators, many of which have informed clinical trials and therapeutic strategies. Additionally, she explores dendritic cell vaccines, immunopeptidomics, and HLA allele influences on transplant success. Her collaborative projects span pediatric and adult immunology, contributing to national consortia such as the Pediatric Transplant and Cellular Therapy Consortium. Her ultimate goal is to enhance survival while reducing toxicities of transplantation through immune-guided, precision medicine approaches. She is especially known for integrating advanced statistical modeling and immunobiology to address real-world clinical challenges.

📚 Publications Top Notes: 

  1. 🧫 Protection of mice against leukemia after vaccination with dendritic cells – Cancer Research (2001)

  2. 💉 Monoclonal anti-IL-6 antibody treatment in B-lymphoproliferative disorder – Blood (2001)

  3. 🧬 CD34+ dendritic cell vaccine induces T-cell immunity in melanoma – J Immunother (2003)

  4. 🦠 Dendritic cells as immune controllers and therapeutic tools – Ann NY Acad Sci (2003)

  5. 🎯 Dendritic cells as vectors for cancer immunotherapy – Semin Cancer Biol (2003)

  6. 🧪 Melanoma vaccines using dendritic cells – Dev Biol Basel (2004)

  7. 🧫 CD8+ T-cell expansion in melanoma patients post-vaccination – J Exp Med (2004)

  8. 🧾 Tumor inhibition assay for CTL response post-vaccine – J Immunother (2005)

  9. 🔁 Peptide-pulsed dendritic cells boost melanoma-specific CD8+ T cells – J Immunother (2005)

  10. 📈 Advances in dendritic cell-based immunotherapy – Adv Exp Med Biol (2005)

🧾 Conclusion:

Dr. Sophie Paczesny embodies the ideal recipient of the Best Researcher Award. She has made transformative contributions to immunology, stem cell biology, and cancer therapeutics, particularly in the field of biomarker-driven precision medicine. Her leadership in both academia and collaborative clinical research has shaped safer and more effective treatment strategies for transplant patients worldwide.

Her depth of expertise, sustained research output, and ongoing innovations place her at the forefront of translational immunology. While minor gains could be made in public visibility and translational enterprise, her impact on science and patient care is profound.

Subodh Kumar | Neuronal Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Subodh Kumar | Neuronal Cell Biology | Best Researcher Award

Assist. Prof. Dr. Subodh Kumar | Texas Tech Univesrity Health Sciences Center El Paso | United States

Dr. Subodh Kumar is an Assistant Professor in Molecular and Translational Medicine at Texas Tech University Health Sciences Center (TTUHSC), El Paso. With a Ph.D. in Molecular Biology from PGIMER, India, and postdoctoral training in Neurobiology at TTUHSC, his work is rooted in understanding neurodegenerative diseases, especially Alzheimer’s disease (AD). He has significantly contributed to identifying synapse-localized microRNAs and their mechanistic roles in AD pathology. Dr. Kumar is the recipient of the prestigious NIH K99/R00 Career Development Award and the Marsh Foundation Research Award. His translational research spans biomarker discovery, synaptic dysfunction, and multi-omics analysis. As a corresponding author on several high-impact publications, Dr. Kumar has developed miRNA-based therapeutic strategies and diagnostics. He serves as an Associate Editor for the Journal of Alzheimer’s Disease and holds memberships in several professional neuroscience organizations. His ongoing research aims to translate molecular findings into innovative treatments for AD.

Publication Profile:

Scopus

✅ Strengths For The Award:

  1. Cutting-edge Research in Alzheimer’s Disease 🧠🧬: Dr. Kumar’s multi-omics and miRNA-focused studies provide novel insights into synaptic dysfunction in Alzheimer’s disease—an area with significant global impact and scientific relevance.

  2. High-impact Publications 📚: His work has appeared in top-tier journals such as Molecular Psychiatry, NPJ Genomic Medicine, Redox Biology, and Human Molecular Genetics—a testament to research quality and scientific contribution.

  3. Leadership & Innovation 🧪: He is the corresponding author on many publications, highlighting leadership in collaborative research. His pioneering discovery of miRNAs like miR-455-3p and miR-502-3p as biomarkers has translational potential.

  4. Consistent Funding & Recognition 💰🏆: Secured prestigious awards like the NIH K99/R00 and Marsh Foundation Research Award, showing trust and acknowledgment from the scientific community.

  5. Mentorship & Editorial Involvement ✏️: Active as an Associate Editor and likely mentoring younger researchers, showcasing academic service and leadership.

⚠️ Areas for Improvement:

  1. Global Collaboration 🌍: Though his current work is impactful, forming more global or cross-institutional collaborations could increase the international visibility of his research.

  2. Public Science Communication 📢: There’s little mention of science outreach or public education; engaging with broader audiences could amplify his societal impact.

  3. Commercialization & Patents: While one patent is listed, further steps toward translational research or biotech partnerships could accelerate clinical applications.

🎓 Education:

Dr. Kumar began his academic journey at CCS University, Meerut, India, where he earned a B.S. in Biology (2004) and an M.S. in Biotechnology (2005). He pursued his doctoral studies at the prestigious Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, where he earned his Ph.D. in Molecular Biology in 2014. His graduate research centered on liver-specific miRNAs in hepatitis C. He further expanded his expertise during a comprehensive postdoctoral training at Texas Tech University Health Sciences Center (TTUHSC), Lubbock, from 2015 to 2021, focusing on neurobiology and Alzheimer’s disease mechanisms. His advanced education combined molecular biology, genomics, and translational neuroscience, laying a solid foundation for his innovative contributions to AD research. Dr. Kumar’s academic training has uniquely equipped him to explore complex disease pathways, develop miRNA-based biomarkers, and use multi-omics approaches for therapeutic target discovery in neurodegeneration.

🧪 Experience:

Dr. Subodh Kumar has nearly two decades of research and academic experience spanning molecular biology, neuroscience, and translational medicine. Currently an Assistant Professor at TTUHSC El Paso (2022–Present), he previously served as a Research Assistant Professor and Postdoctoral Fellow at TTUHSC Lubbock (2015–2022). His early career included roles as a Senior and Junior Research Fellow at ICMR, India, and as a tutor in Biotechnology. He has mentored multiple students and leads independent NIH-funded research investigating microRNA roles in Alzheimer’s disease. Notably, his pioneering studies on synapse-localized miRNAs and multi-omics integration have shed light on novel targets and mechanisms underlying AD pathogenesis. He has also worked on liver-related miRNAs and their biomarker potential during hepatitis C virus infections. With a well-rounded profile combining teaching, laboratory research, and grant writing, Dr. Kumar’s experience reflects strong leadership in collaborative, interdisciplinary, and translational research.

🏅 Awards and Honors:

Dr. Kumar has received numerous accolades throughout his career, highlighting both his scientific excellence and research impact. Most notably, he was awarded the NIH NIA K99/R00 Pathway to Independence Award in 2020, supporting his pioneering work on microRNA in Alzheimer’s disease. In 2024, he received the Marsh Foundation Research Award at TTUHSC El Paso. His presentations and posters have been recognized at institutional and national levels, including the Best Oral Presentation Award at the 14th Annual Research Symposium (2022) and the Best Poster Award at the Healthy Aging and Dementia Symposium (2018). He has also received competitive fellowships and travel awards from prestigious Indian agencies such as CSIR and ICMR, including an International Travel Award and GATE fellowship. These honors reflect Dr. Kumar’s sustained excellence in translational neuroscience, innovation in biomarker discovery, and leadership in Alzheimer’s disease research.

🧬 Research Focus:

Dr. Subodh Kumar’s research focuses on the molecular mechanisms of synaptic dysfunction in Alzheimer’s disease (AD), with particular emphasis on synapse-localized microRNAs (miRNAs). His lab explores how deregulated miRNAs like miR-501-3p, miR-502-3p, and miR-455-3p affect synaptic protein expression, GABAergic function, and mitochondrial dynamics. Dr. Kumar integrates multi-omics approaches—including transcriptomics, proteomics, and miRNA sequencing—on human brain-derived synaptosomes to uncover novel biomarkers and therapeutic targets. His group also uses lentiviral vector systems and stereotaxic injections in mouse models to manipulate miRNA expression in vivo. These findings help clarify miRNA-mRNA-protein interactions in AD progression. Dr. Kumar also explores the diagnostic potential of miRNAs using patient-derived samples (CSF, serum, fibroblasts). His research bridges basic neuroscience with clinical translation, aiming to develop miRNA-based therapeutics and non-invasive diagnostic panels for early AD detection. His work holds promise in reshaping our understanding and treatment of neurodegenerative diseases.

📚 Publication Titles Top Notes:

  1. 🧠 Integrated multi-omics analyses of synaptosomes revealed synapse-associated novel targets in Alzheimer’s disease (Molecular Psychiatry, 2025)

  2. 🧬 MiRNA-501-3p and MiRNA-502-3p: a promising biomarker panel for Alzheimer’s disease (Clinical and Translational Medicine, 2025)

  3. 🧩 MicroRNA-502-3p Modulates the GABA A Subunits, Synaptic Proteins, and Mitochondrial Morphology in Hippocampal Neurons (Molecular Neurobiology, 2025)

  4. 🔬 MicroRNA-502-3p regulates GABAergic synapse function in hippocampal neurons (Neural Regeneration Research, 2024)

  5. 🧠 Synaptosome microRNAs regulate synapse functions in Alzheimer’s disease (NPJ Genomic Medicine, 2022)

  6. 🧪 MicroRNA-455-3p improves synaptic, cognitive functions and extends lifespan: relevance to Alzheimer’s disease (Redox Biology, 2021)

  7. 🧠 Novel MicroRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer’s disease (BBA, 2019)

  8. 🧬 MicroRNA-455-3p as a potential biomarker for Alzheimer’s disease: an update (Frontiers in Aging Neuroscience, 2018)

  9. 🧪 MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease (Human Molecular Genetics, 2017)

  10. 🧫 Crosstalk between microRNA-122 and FOX family genes in HepG2 cells (Exp Biology & Medicine, 2017)

📌 Conclusion:

Dr. Subodh Kumar is a highly suitable candidate for the Best Researcher Award. His research on microRNAs in neurodegeneration is groundbreaking, well-funded, and internationally recognized. With a robust publication record, academic leadership, and translational potential, he exemplifies the caliber expected of this distinction. Strategic enhancements in international outreach and translational ventures would further elevate his global impact.

Carlos Cruchaga | Neuronal Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Carlos Cruchaga | Neuronal Cell Biology | Best Researcher Award

Dr. Carlos Cruchaga, Washington Univeristy, United States

Dr. Carlos Cruchaga is a tenured Professor at Washington University School of Medicine, with joint appointments in Psychiatry, Genetics, and Neurology. He is the Director of the NeuroGenomics and Informatics Center and leads multiple high-impact cores including the Knight ADRC, DIAN Genetics Core, and Biorepository Core for initiatives like the Dystonia Coalition and Aging Adult Brain Connectome. Internationally recognized for his pioneering work in neurodegenerative diseases, Dr. Cruchaga specializes in integrating multi-omic datasets to identify novel genetic and molecular mechanisms underlying Alzheimer’s disease and other neurological disorders. He has authored over 340 peer-reviewed publications and continues to lead major NIH-funded projects. With a strong commitment to translational research, he also contributes to tool development for omics data analysis. His work consistently bridges the gap between basic research and clinical application, making him a deserving candidate for the Best Researcher Award.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  • Leadership: Director of NeuroGenomics and Informatics Center; leads major genetics cores (Knight ADRC, DIAN, Dystonia Coalition, AABC).

  • Research Impact: Over 346 peer-reviewed publications with significant contributions in Alzheimer’s Disease (AD), neurodegeneration, multi-omics, and genetic epidemiology.

  • Translational Focus: Discoveries such as rare variants in AD-related genes (APP, PSEN1, PSEN2, PLD3, TREM2) and biomarker identification have major clinical implications.

  • Global Collaborations: Works with international research consortia including ADNI, GERAD, and Alzheimer’s Research UK, showing both scientific influence and collaboration.

  • Recognition: Invited speaker at high-level conferences; selected for the prestigious Spanish “Excellence Campus 2005”.

  • Innovation: Pioneered multi-omic and bioinformatic pipelines for biomarker discovery.

⚠️ Areas for Improvement:

  • Public Outreach: While academically exceptional, public or patient-facing outreach or science communication isn’t highlighted.

  • Diversity Initiatives: Potential to expand into mentorship programs or initiatives focused on increasing diversity in genomics.

  • Commercialization: There is room to emphasize translational science through startups, patents, or technology transfer.

🎓 Education:

Dr. Cruchaga earned his undergraduate degree in Biochemistry from the University of Navarra, Pamplona, Spain (1996–2000). He continued his graduate studies at the same institution, obtaining an MA (2000–2002) followed by a PhD in Biochemistry and Molecular Biology in 2005. His doctoral research, awarded Summa Cum Laude, focused on molecular mechanisms and biomarkers associated with neurodegenerative diseases. Dr. Cruchaga was selected among Spain’s top 18 PhD students to present his research at the “Excellence Campus 2005,” hosted by the Spanish Government and attended by Nobel Laureates. His training included foundational roles as a student and teaching assistant in the Department of Biochemistry and Molecular Biology, setting the stage for a career deeply rooted in research excellence and academic mentorship. This strong academic background has been instrumental in shaping his translational approach to complex neurological conditions like Alzheimer’s and dystonia.

💼 Experience:

Dr. Cruchaga has amassed extensive experience across academic, administrative, and research leadership roles. Since 2019, he has served as a Professor in Psychiatry, Genetics, and Neurology at Washington University. He is also the current Director of the NeuroGenomics and Informatics Center (since 2018), where he supervises multi-disciplinary teams and oversees high-throughput genomics operations. He leads cores in major initiatives such as the Knight Alzheimer’s Disease Research Center (ADRC), DIAN (Dominantly Inherited Alzheimer Network), and the Dystonia Coalition. Earlier roles include serving on the Alzheimer’s Association International Conference Scientific Program Committee (2014–2017), where he curated session topics, evaluated hundreds of abstracts, and chaired sessions. His international collaborations span omics, imaging, and computational biology, making him a leader in neurogenomics. These diverse roles have allowed Dr. Cruchaga to influence both scientific innovation and strategic planning within global neuroscience research initiatives.

🏅 Honors and Awards:

Dr. Cruchaga’s excellence has been recognized through numerous awards and invitations. In 2005, he was chosen for “Excellence Campus 2005,” a prestigious event featuring the top Spanish PhD students alongside Nobel Prize winners. He has received multiple invitations for keynote lectures and seminars at institutions across Europe and the U.S., including the University of the Basque Country, the Center for Applied Medical Research in Pamplona, and Washington University. He was a finalist for the O’Leary Award for Research in Neuroscience in 2009. His service as a Scientific Program Committee Member for the Alzheimer’s Association International Conference further underscores his leadership in the field. These accolades not only celebrate his scientific contributions but also affirm his status as a thought leader in neurodegenerative disease research. His peer-reviewed work has appeared in top-tier journals like Nature, Neuron, and Acta Neuropathologica.

🔬 Research Focus:

Dr. Cruchaga’s research centers on understanding the molecular and genetic underpinnings of neurodegenerative diseases, particularly Alzheimer’s disease, using integrative multi-omics approaches. His lab specializes in analyzing genomic, transcriptomic, proteomic, and metabolomic data from human biospecimens to uncover biomarkers, risk variants, and causal pathways. He has led groundbreaking studies identifying rare coding variants in genes like TREM2, PLD3, and APP, linking them to Alzheimer’s pathology. He applies advanced computational tools and machine learning to interpret high-dimensional data and translate findings into diagnostic and therapeutic strategies. As director of several national consortia cores (e.g., Knight ADRC, DIAN), he facilitates data-sharing and harmonization across global cohorts. His work also explores the genetic architecture of disorders like dystonia and peripheral neuropathy. The long-term goal of his research is to bridge omics data with clinical outcomes to enable personalized medicine in neurology.

📚 Publications Top Notes:

  1. 🧠 Rare variants in APP, PSEN1 and PSEN2 increase AD risk in late-onset families – PLoS One (2012)

  2. 🧬 GWAS of CSF tau levels reveals novel AD risk variants – Neuron (2013)

  3. 🧠 Rare coding variants in PLD3 gene confer AD risk – Nature (2014)

  4. 🧠 TREM2 coding variants increase AD risk – Human Molecular Genetics (2014)

  5. 🧪 TREM2 variants linked to AD risk in African Americans – Mol Neurodegeneration (2015)

  6. 🧫 Higher CSF soluble TREM2 linked to AD mutation status – Acta Neuropathologica (2016)

  7. 🧪 Genetics of plasma analytes identifies novel biomarkers – Scientific Reports (2016)

  8. 🧬 Variants in Mendelian AD genes within ADSP – JAD (2025)

  9. 🧠 RFC1 AAGGG repeat expansions common in neuropathy – Preprint (2025)

  10. 🧪 Plasma proteomics uncovers novel AD biomarkers – Preprint (2025)

🧾 Conclusion:

Dr. Carlos Cruchaga exemplifies the highest standards of neuroscience and genomics research. His contributions have advanced the global understanding of Alzheimer’s disease, making him a top-tier candidate for the Best Researcher Award. His scientific leadership, prolific output, and translational success position him as a standout in the biomedical field.